Editorial comment on “Dutasteride, a 5 alpha‐reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia”

Ähnliche Einträge

• Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia
  von: So Inamura, et al.
  Veröffentlicht: (2024)
• Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options
  von: So Inamura, et al.
  Veröffentlicht: (2024)
• Editorial Comment on “Initial outcomes and surgical techniques of prostatic urethral lift for benign prostatic hyperplasia in Japan”
  von: Takafumi Yagisawa, et al.
  Veröffentlicht: (2024)
• Quality of life and influencing factors in older adults with benign prostatic hyperplasia
  von: Chen‐ke Wang, et al.
  Veröffentlicht: (2024)
• Evaluation of learning curves for contact laser vaporization of the prostate using the 980 nm diode laser for benign prostatic hyperplasia
  von: Jun Furumido, et al.
  Veröffentlicht: (2024)